PortalPublikationenPrediction of the estimated 5-year risk of sudden cardiac de...

Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR

Standard

Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. / Avanesov, Maxim; Münch, Julia; Weinrich, Julius; Well, Lennart; Säring, Dennis; Stehning, Christian; Tahir, Enver; Bohnen, Sebastian; Radunski, Ulf K; Muellerleile, Kai; Adam, Gerhard; Patten, Monica; Lund, Gunnar.

in: EUR RADIOL, Jahrgang 27, Nr. 12, 12.2017, S. 5136-5145.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Avanesov, M, Münch, J, Weinrich, J, Well, L, Säring, D, Stehning, C, Tahir, E, Bohnen, S, Radunski, UK, Muellerleile, K, Adam, G, Patten, M & Lund, G 2017, 'Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR', EUR RADIOL, Jg. 27, Nr. 12, S. 5136-5145. https://doi.org/10.1007/s00330-017-4869-x

APA

Avanesov, M., Münch, J., Weinrich, J., Well, L., Säring, D., Stehning, C., Tahir, E., Bohnen, S., Radunski, U. K., Muellerleile, K., Adam, G., Patten, M., & Lund, G. (2017). Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. EUR RADIOL, 27(12), 5136-5145. https://doi.org/10.1007/s00330-017-4869-x

Vancouver

Avanesov M, Münch J, Weinrich J, Well L, Säring D, Stehning C et al. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR. EUR RADIOL. 2017 Dez;27(12):5136-5145. https://doi.org/10.1007/s00330-017-4869-x

Bibtex

@article{a6078906a6ac479cb0a6affa6748a823,
title = "Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR",
abstract = "OBJECTIVES: To evaluate the ability of late gadolinium enhancement (LGE) and mapping cardiac magnetic resonance (CMR) including native T1 and global extracellular volume (ECV) to identify hypertrophic cardiomyopathy (HCM) patients at risk for sudden cardiac death (SCD) and to predict syncope or non-sustained ventricular tachycardia (VT).METHODS: A 1.5-T CMR was performed in 73 HCM patients and 16 controls. LGE size was quantified using the 3SD, 5SD and full width at half maximum (FWHM) method. T1 and ECV maps were generated by a 3(3)5 modified Look-Locker inversion recovery sequence. Receiver-operating curve analysis evaluated the best parameter to identify patients with increased SCD risk ≥4% and patients with syncope or non-sustained VT.RESULTS: Global ECV was the best predictor of SCD risk with an area under the curve (AUC) of 0.83. LGE size was significantly inferior to global ECV with an AUC of 0.68, 0.70 and 0.70 (all P < 0.05) for 3SD-, 5SD- and FWHM-LGE, respectively. Combined use of the SCD risk score and global ECV significantly improved the diagnostic accuracy to identify HCM patients with syncope or non-sustained VT.CONCLUSIONS: Combined use of the SCD risk score and global ECV has the potential to improve HCM patient selection, benefiting most implantable cardioverter defibrillators.KEY POINTS: • Global ECV identified the best HCM patients with increased SCD risk. • Global ECV performed equally well compared to a SCD risk score. • Combined use of the SCD risk score and global ECV improved test accuracy. • Combined use potentially improves selection of HCM patients for ICD implantation.",
keywords = "Journal Article",
author = "Maxim Avanesov and Julia M{\"u}nch and Julius Weinrich and Lennart Well and Dennis S{\"a}ring and Christian Stehning and Enver Tahir and Sebastian Bohnen and Radunski, {Ulf K} and Kai Muellerleile and Gerhard Adam and Monica Patten and Gunnar Lund",
year = "2017",
month = dec,
doi = "10.1007/s00330-017-4869-x",
language = "English",
volume = "27",
pages = "5136--5145",
journal = "EUR RADIOL",
issn = "0938-7994",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR

AU - Avanesov, Maxim

AU - Münch, Julia

AU - Weinrich, Julius

AU - Well, Lennart

AU - Säring, Dennis

AU - Stehning, Christian

AU - Tahir, Enver

AU - Bohnen, Sebastian

AU - Radunski, Ulf K

AU - Muellerleile, Kai

AU - Adam, Gerhard

AU - Patten, Monica

AU - Lund, Gunnar

PY - 2017/12

Y1 - 2017/12

N2 - OBJECTIVES: To evaluate the ability of late gadolinium enhancement (LGE) and mapping cardiac magnetic resonance (CMR) including native T1 and global extracellular volume (ECV) to identify hypertrophic cardiomyopathy (HCM) patients at risk for sudden cardiac death (SCD) and to predict syncope or non-sustained ventricular tachycardia (VT).METHODS: A 1.5-T CMR was performed in 73 HCM patients and 16 controls. LGE size was quantified using the 3SD, 5SD and full width at half maximum (FWHM) method. T1 and ECV maps were generated by a 3(3)5 modified Look-Locker inversion recovery sequence. Receiver-operating curve analysis evaluated the best parameter to identify patients with increased SCD risk ≥4% and patients with syncope or non-sustained VT.RESULTS: Global ECV was the best predictor of SCD risk with an area under the curve (AUC) of 0.83. LGE size was significantly inferior to global ECV with an AUC of 0.68, 0.70 and 0.70 (all P < 0.05) for 3SD-, 5SD- and FWHM-LGE, respectively. Combined use of the SCD risk score and global ECV significantly improved the diagnostic accuracy to identify HCM patients with syncope or non-sustained VT.CONCLUSIONS: Combined use of the SCD risk score and global ECV has the potential to improve HCM patient selection, benefiting most implantable cardioverter defibrillators.KEY POINTS: • Global ECV identified the best HCM patients with increased SCD risk. • Global ECV performed equally well compared to a SCD risk score. • Combined use of the SCD risk score and global ECV improved test accuracy. • Combined use potentially improves selection of HCM patients for ICD implantation.

AB - OBJECTIVES: To evaluate the ability of late gadolinium enhancement (LGE) and mapping cardiac magnetic resonance (CMR) including native T1 and global extracellular volume (ECV) to identify hypertrophic cardiomyopathy (HCM) patients at risk for sudden cardiac death (SCD) and to predict syncope or non-sustained ventricular tachycardia (VT).METHODS: A 1.5-T CMR was performed in 73 HCM patients and 16 controls. LGE size was quantified using the 3SD, 5SD and full width at half maximum (FWHM) method. T1 and ECV maps were generated by a 3(3)5 modified Look-Locker inversion recovery sequence. Receiver-operating curve analysis evaluated the best parameter to identify patients with increased SCD risk ≥4% and patients with syncope or non-sustained VT.RESULTS: Global ECV was the best predictor of SCD risk with an area under the curve (AUC) of 0.83. LGE size was significantly inferior to global ECV with an AUC of 0.68, 0.70 and 0.70 (all P < 0.05) for 3SD-, 5SD- and FWHM-LGE, respectively. Combined use of the SCD risk score and global ECV significantly improved the diagnostic accuracy to identify HCM patients with syncope or non-sustained VT.CONCLUSIONS: Combined use of the SCD risk score and global ECV has the potential to improve HCM patient selection, benefiting most implantable cardioverter defibrillators.KEY POINTS: • Global ECV identified the best HCM patients with increased SCD risk. • Global ECV performed equally well compared to a SCD risk score. • Combined use of the SCD risk score and global ECV improved test accuracy. • Combined use potentially improves selection of HCM patients for ICD implantation.

KW - Journal Article

U2 - 10.1007/s00330-017-4869-x

DO - 10.1007/s00330-017-4869-x

M3 - SCORING: Journal article

C2 - 28616729

VL - 27

SP - 5136

EP - 5145

JO - EUR RADIOL

JF - EUR RADIOL

SN - 0938-7994

IS - 12

ER -